Demonstrating laboratory proficiency in bacterial mutagenicity assays for regulatory submission.

The bacterial reverse mutation test is a mainstay for evaluation of mutagenicity predicting the carcinogenic potential of a test substance and is recommended by regulatory agencies across the globe. The popularity of the test is due, in part, to the relatively low cost, rapid results and small amount of test material required compared to most other toxicological tests as well as the near universal acceptance of the toxicological significance of a clear positive or negative result. Most laboratories follow the Organization for Economic Cooperation and Development Test Guideline 471 (TG471) or national guidelines based on TG471. Regulatory agencies in most countries are obligated to consider results from tests which meet the recommendations laid out in TG471. Nonetheless, laboratories unfamiliar with the test sometimes have trouble generating reliable, reproducible results. TG471 is a test guideline, not a detailed test protocol. A group of experts from regulatory agencies and laboratories which use the assay has assembled here a set of recommendations which if followed, will allow an inexperienced laboratory to acquire proficiency in assay conduct. These include recommendations for how to create a cell bank for the 5 Salmonella typhimurium/Escherichia coli strains and develop a laboratory protocol to reliably culture each strain to ensure each culture has the characteristics which allow adequate sensitivity for detection of mutagens using the test as described in TG471. By testing compounds on the provided lists of positive and negative test substances, the laboratory will have surmounted many of the problems commonly encountered during routine testing of unknown chemicals and will have gained the experience necessary to prepare the detailed protocol needed for performing the test under Good Laboratory Procedures and the laboratory will have generated the historical positive and negative control databases which are needed for test reports which adhere to TG471.

[1]  L. Claxton,et al.  Vaporization technique to measure mutagenic activity of volatiles organic chemicals in the Ames/Salmonella assay. , 1987, Environmental mutagenesis.

[2]  Rita Schoeny,et al.  Main issues addressed in the 2014–2015 revisions to the OECD Genetic Toxicology Test Guidelines , 2017, Environmental and molecular mutagenesis.

[3]  N. Ozawa,et al.  Difference in liver homogenates from Donryu, Fischer, Sprague-Dawley and Wistar strains of rat in the drug-metabolizing enzyme assay and the Salmonella/hepatic S9 activation test. , 1982, Mutation research.

[4]  Anomalous mutagenicity profile of cyclohexanone oxime in bacteria: cell survival in background lawns. , 2001, Mutation research.

[5]  E. Zeiger,et al.  Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals , 1992, Environmental and molecular mutagenesis.

[6]  A. Araki,et al.  Improved method for mutagenicity testing of gaseous compounds by using a gas sampling bag. , 1994, Mutation research.

[7]  Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study , 2018, Genes and Environment.

[8]  C. Elcombe,et al.  Evaluation of phenobarbital/beta-naphthoflavone as an alternative S9-induction regime to Aroclor 1254 in the rat for use in in vitro genotoxicity assays. , 1995, Mutagenesis.

[9]  E. Zeiger,et al.  Guide for the Salmonella typhimurium/mammalian microsome tests for bacterial mutagenicity. , 1987, Mutation research.

[10]  V. Mitchell,et al.  Mutagenicity of benzidine and benzidine-congener dyes and selected monoazo dyes in a modified Salmonella assay. , 1984, Mutation research.

[11]  C. Ioannides,et al.  Cytosolic activation of 2-aminoanthracene: implications in its use as diagnostic mutagen in the Ames test. , 1992, Mutation research.

[12]  Alexander Amberg,et al.  Do Carboxylic/Sulfonic Acid Halides Really Present a Mutagenic and Carcinogenic Risk as Impurities in Final Drug Products? , 2015 .

[13]  T. Satoh,et al.  Advantage of the use of human materials in the safety assessment of chemicals: the Ames test using human S9 , 2003 .

[14]  Tetsuo Satoh,et al.  Salmonella/human S9 mutagenicity test: a collaborative study with 58 compounds. , 2005, Mutagenesis.

[15]  B. Ames,et al.  Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.

[16]  T Ohta,et al.  Recommendations for the performance of bacterial mutation assays. , 1994, Mutation research.

[17]  N. Chauret,et al.  Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[18]  R. Mayer,et al.  Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. , 1985, Biochemical pharmacology.

[19]  H. Yamazaki,et al.  Inhibitory effect of organic solvents on the mutagenicity of N-nitrosodialkylamines in Salmonella. , 1985, Mutation research.

[20]  K. Tsukidate,et al.  Inhibitory Effect of Dimethyl Sulfoxide on the Mutagenicity of Promutagens in the Ames Test , 2010 .

[21]  Tsuneo Hashizume,et al.  The utility of metabolic activation mixtures containing human hepatic post-mitochondrial supernatant (S9) for in vitro genetic toxicity assessment. , 2016, Mutagenesis.

[22]  Daniel Swern,et al.  Activated Dimethyl Sulfoxide: Useful Reagents for Synthesis , 1981 .

[23]  B. Ames,et al.  Compatibility of organic solvents with the Salmonella/microsome test. , 1981, Mutation research.

[24]  D. Snodin,et al.  Potentially Mutagenic Impurities (PMIs): Optimizing Toxicological and Analytical Assessments , 2014 .

[25]  E. Zeiger,et al.  The Ames Salmonella/microsome mutagenicity assay. , 2000, Mutation research.

[26]  T. Kamataki,et al.  Metabolic activation of mutagenic tryptophan pyrolysis products by rat liver microsomes. , 1980, Cancer research.